Repare Therapeutics Inc · Q1 2022 earnings

Briefing

Reported financial results for the first quarter ended March 31, 2022.

Repare Therapeutics reported a net loss of $34.8 million, or $0.83 per share, for the first quarter ended March 31, 2022. The company's cash and cash equivalents and marketable securities totaled $311.7 million as of March 31, 2022. Significant progress was made in the RP-3500 program, highlighted by a comprehensive new dataset from the TRESR trial presented at the AACR conference.

• Updated clinical data from the Phase 1/2 TRESR clinical trial of camonsertib showed durable clinical benefit across tumor types and genomic alterations.
• Camonsertib monotherapy continues to appear safe and well tolerated, with anemia being the most common reported toxicity.
• Preclinical data demonstrating the potential of PKMYT1 inhibitor RP-6306 in tumors with CCNE1 amplification was published in Nature.
• Patient enrollment initiated in a new arm of its Phase 1 MYTHIC clinical trial designed to evaluate the safety and tolerability of RP-6306 in combination with camonsertib in patients with advanced solid tumors

Headline financials

Revenue & EPS history

The company looks forward to providing updates on the potential of camonsertib as monotherapy and initial data of camonsertib in combination with PARP inhibitors or gemcitabine expected in the second half of this year.